These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 7756739)

  • 21. [Polycystic kidney diseases: molecular genetics and counselling].
    Lespinasse J; Fourcade J; Schir F
    Nephrol Ther; 2006 Jul; 2(3):120-6. PubMed ID: 16890136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.
    Stayner C; Iglesias DM; Goodyer PR; Ellis L; Germino G; Zhou J; Eccles MR
    Hum Mol Genet; 2006 Dec; 15(24):3520-8. PubMed ID: 17082250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways.
    Happé H; Leonhard WN; van der Wal A; van de Water B; Lantinga-van Leeuwen IS; Breuning MH; de Heer E; Peters DJ
    Hum Mol Genet; 2009 Jul; 18(14):2532-42. PubMed ID: 19401297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
    Banković-Calić N; Ogbori MR; Nicman E
    Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polycystic kidney disease: etiology, pathogenesis, and treatment.
    Martinez JR; Grantham JJ
    Dis Mon; 1995 Nov; 41(11):693-765. PubMed ID: 7587886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphology of cystic renal lesions. Lectin and immuno-histochemical study.
    Kovács J; Zilahy M; Gomba S
    Acta Chir Hung; 1997; 36(1-4):176-8. PubMed ID: 9408336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
    Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine, endocrine and paracrine regulation of growth abnormalities in autosomal dominant polycystic kidney disease.
    Wilson PD; Du J; Norman JT
    Eur J Cell Biol; 1993 Jun; 61(1):131-8. PubMed ID: 8223698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
    Grantham JJ; Chapman AB; Torres VE
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):148-57. PubMed ID: 17699202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polycystic kidney disease: primary extracellular matrix abnormality or defective cellular differentiation?
    Calvet JP
    Kidney Int; 1993 Jan; 43(1):101-8. PubMed ID: 8433548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine models of polycystic kidney disease: molecular and therapeutic insights.
    Guay-Woodford LM
    Am J Physiol Renal Physiol; 2003 Dec; 285(6):F1034-49. PubMed ID: 14600027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Notch3 in Renal Tubular Cells Leads to Progressive Cystic Kidney Disease.
    Djudjaj S; Kavvadas P; Prakoura N; Bülow RD; Migeon T; Placier S; Chadjichristos CE; Boor P; Chatziantoniou C
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
    Covic M; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential causes and pathogenesis in autosomal dominant polycystic kidney disease.
    Milutinovic J; Agodoa LY
    Nephron; 1983; 33(2):139-44. PubMed ID: 6835461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease.
    Ramasubbu K; Gretz N; Bachmann S
    J Am Soc Nephrol; 1998 Jun; 9(6):937-45. PubMed ID: 9621276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis.
    Zhou XJ; Kukes G
    Diagn Mol Pathol; 1998 Apr; 7(2):65-8. PubMed ID: 9785003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease.
    Li KJ; Shiau AL; Chiou YY; Yo YT; Wu CL
    Kidney Int; 2005 May; 67(5):1710-22. PubMed ID: 15840017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights into the molecular pathophysiology of polycystic kidney disease.
    Murcia NS; Sweeney WE; Avner ED
    Kidney Int; 1999 Apr; 55(4):1187-97. PubMed ID: 10200981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant epithelial cell growth in autosomal dominant polycystic kidney disease.
    Wilson PD
    Am J Kidney Dis; 1991 Jun; 17(6):634-7. PubMed ID: 2042637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?
    Edelstein CL
    Cell Cycle; 2005 Nov; 4(11):1550-4. PubMed ID: 16258272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.